Victory Capital Management Inc. Increases Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Victory Capital Management Inc. raised its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 13.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 87,130 shares of the medical equipment provider’s stock after purchasing an additional 10,297 shares during the period. Victory Capital Management Inc.’s holdings in Lantheus were worth $7,795,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Wilmington Savings Fund Society FSB purchased a new stake in shares of Lantheus in the third quarter valued at about $25,000. Kestra Investment Management LLC purchased a new stake in shares of Lantheus in the fourth quarter valued at about $27,000. UMB Bank n.a. lifted its holdings in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares in the last quarter. RiverPark Advisors LLC purchased a new stake in shares of Lantheus in the third quarter valued at about $74,000. Finally, Parkside Financial Bank & Trust lifted its holdings in shares of Lantheus by 49.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock valued at $76,000 after purchasing an additional 280 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Buying and Selling

In other news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares of the company’s stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

LNTH has been the subject of a number of analyst reports. JMP Securities reissued a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial boosted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Finally, The Goldman Sachs Group initiated coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $132.86.

Lantheus Stock Performance

Shares of LNTH stock opened at $101.10 on Friday. Lantheus Holdings, Inc. has a one year low of $56.44 and a one year high of $126.89. The company has a 50 day moving average price of $91.87 and a 200 day moving average price of $96.90. The firm has a market capitalization of $6.92 billion, a price-to-earnings ratio of 16.82 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. As a group, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.